FIELD: medicine.
SUBSTANCE: what is presented is a method for providing syalidase enzymatic activity in a cell line culture on the basis of cell transfection by a polypeptide expression vector having syalidase activity and containing a sequence coding a catalytic domain of the enzyme syalidase with a lower number of sialic acid residues wherein polypeptide is secreted into a medium together with Fc-containing protein. What is also presented is a related vector. The invention is applicable in treating diseases and conditions requiring the control of affinity to one or more FcγRI, FcγRllA and FcγRIIIA receptors, ADCC activity, macrophague or monocyte activation, half-life in a serum and avidity.
EFFECT: higher effectiveness of the use of the invention.
14 cl, 14 dwg, 4 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREPARING ANTIBODIES HAVING IMPROVED PROPERTIES | 2011 |
|
RU2604811C2 |
| METHOD OF DESTROYING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES | 2007 |
|
RU2429246C2 |
| ANTIBODY Fc VARIANTS | 2012 |
|
RU2607014C2 |
| MULTI-SPECIFIC OR BISPECIFIC MOLECULE (VERSIONS), METHOD FOR ELIMINATION OR DECREASING QUANTITY OF TARGET CELLS IN SUBJECT'S BODY, METHOD FOR TREATING PATHOGEN-INFECTED SUBJECT AND METHOD FOR SUBJECT'S VACCINATION | 1997 |
|
RU2201766C2 |
| ANTIBODIES AGAINST A2 TENASTIN-C AND METHODS FOR USE THEREOF | 2011 |
|
RU2584597C2 |
| COMPOSITION COMPRISING TWO ANTIBODIES ENGINEERED TO HAVE REDUCED AND INCREASED EFFECTOR FUNCTION | 2013 |
|
RU2650788C2 |
| AFFINITY-MATURED HUMANISED ANTI-CEA MONOCLONAL ANTIBODIES | 2010 |
|
RU2570554C2 |
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF | 2014 |
|
RU2815683C2 |
| STABLE MULTI-SPECIFIC ANTIBODIES | 2018 |
|
RU2779602C2 |
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF THEIR APPLICATION | 2014 |
|
RU2727836C2 |
